These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11055154)

  • 41. Can price and regulatory controls replace free market competition in the drug industry?
    Buc NL; Levitt GM
    Healthspan; 1993 Nov; 10(10):30-2. PubMed ID: 10130839
    [No Abstract]   [Full Text] [Related]  

  • 42. The potential for self-interested behavior by pharmaceutical manufacturers through vertical integration with pharmacy benefit managers: the need for a new regulatory approach.
    Mitchell EL
    Food Drug Law J; 1999; 54(1):151-83. PubMed ID: 11758556
    [No Abstract]   [Full Text] [Related]  

  • 43. Feds need to get back in the game. Challenging anticompetitive hospital mergers keeps prices down, quality up.
    Balto D
    Mod Healthc; 2002 Apr; 32(17):25. PubMed ID: 12024770
    [No Abstract]   [Full Text] [Related]  

  • 44. The stifling of competition by the antitrust laws: the irony of the health care industry.
    Powers JA
    J Law Health; 2000-2001; 15(2):223-46. PubMed ID: 12238323
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharmaceutical manufacturers seek OIG comfort.
    Becker S
    Health Care Law Mon; 2002 Aug; ():3-6. PubMed ID: 12420396
    [No Abstract]   [Full Text] [Related]  

  • 46. What can Johnson & Johnson do to remain a giant in the health care industry?
    Carter T
    J Hosp Mark Public Relations; 2002; 14(1):93-103. PubMed ID: 12569997
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A whole new world?: pharmaceutical responses to the managed care revolution.
    Balto DA
    Food Drug Law J; 1997; 52(1):83-98. PubMed ID: 10346712
    [No Abstract]   [Full Text] [Related]  

  • 48. Collective bargaining & anti trust.
    Droste T
    Healthplan; 1999; 40(5):44-8, 50. PubMed ID: 10622967
    [No Abstract]   [Full Text] [Related]  

  • 49. Market exclusivity after a prescription to nonprescription drug switch: striking the right balance between innovation and competition.
    Kraushaar KJ
    Food Drug Law J; 1999; 54(2):243-4. PubMed ID: 11758581
    [No Abstract]   [Full Text] [Related]  

  • 50. Drug sampling: legislation proposed; industry receptive to ending practice.
    Gatty B
    Hosp Formul; 1994 Jun; 29(6):478, 477. PubMed ID: 10134577
    [No Abstract]   [Full Text] [Related]  

  • 51. Key compliance concerns for the generic pharmaceutical industry.
    Werling K; Enyeart A
    Health Care Law Mon; 2009 Jul; 2009(7):2-6. PubMed ID: 19618761
    [No Abstract]   [Full Text] [Related]  

  • 52. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 53. Entry order as a consideration for innovation strategies.
    Cohen FJ
    Nat Rev Drug Discov; 2006 Apr; 5(4):285-93. PubMed ID: 16531989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antitrust laws.
    Razor J
    Bull Am Coll Surg; 2003 Apr; 88(4):8-10. PubMed ID: 23581084
    [No Abstract]   [Full Text] [Related]  

  • 55. Health care collaboration, antitrust, and the 1992 merger guidelines: do competition and cost effective co-operation conflict?
    Adler H
    J Health Hosp Law; 1992 Jul; 25(7):193-200. PubMed ID: 10123591
    [No Abstract]   [Full Text] [Related]  

  • 56. Perspectives. Antitrust looming larger for health care institutions.
    Moskowitz DB
    Faulkner Grays Med Health; 1991 Oct; 45(41):suppl 4 p.. PubMed ID: 10114312
    [No Abstract]   [Full Text] [Related]  

  • 57. FTC-DOJ report affirms value of health care competition.
    Kertesz L
    AHIP Cover; 2004; 45(6):13, 71-3. PubMed ID: 15700871
    [No Abstract]   [Full Text] [Related]  

  • 58. FTC approves Lilly's PCS purchase.
    Scott L
    Mod Healthc; 1995 Aug; 25(32):30. PubMed ID: 10144477
    [No Abstract]   [Full Text] [Related]  

  • 59. Hospital markets and competition: implications for antitrust policy.
    Nguyen NX; Derrick FW
    Health Care Manage Rev; 1994; 19(1):34-43. PubMed ID: 8206760
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A conflict of interest: why peer review committees need heightened scrutiny under federal antitrust law.
    Rakestraw E
    J Leg Med; 2009; 30(4):563-78. PubMed ID: 19953408
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.